Independent public inquiries needed to ensure drug safetyBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6336 (Published 16 November 2010) Cite this as: BMJ 2010;341:c6336
- Brian Edwards, pharmacovigilance consultant1
- 1Ashtead, Surrey KT21 1PX, UK
Cohen’s article on rosiglitazone asks whether regulators, industry, and the clinical community will do a better job next time.1 What is the evidence that “anything” went wrong or “anyone” did anything wrong? How can a drug safety regulator allege that a drug may have caused thousands of excess deaths …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial